SCHEMBL514505

SCHEMBL514505

CC(C)(C)N(C(=O)O)[C@]1(c2ccc(C(=O)C(Br)c3ccccc3)cc2)C[C@](C)(O)C1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 2/20 0.34
CES1 P23141 2/20 0.34
TDP1 Q9NUW8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
OPRM1 P35372 1/20 0.33
OPRL1 P41146 1/20 0.33
KDM4E B2RXH2 2/20 0.33
ALDH1A1 P00352 2/20 0.33
MAPT P10636 2/20 0.31
TP53 P04637 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP2C9 P11712 1/20 0.31
TSHR P16473 1/20 0.31
CYP2C19 P33261 1/20 0.31
LMNA P02545 2/20 0.30
HSD17B10 Q99714 1/20 0.30
AOC3 Q16853 1/20 0.30
POLB P06746 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL514506 1.00 CES2 (0.34) CES2CES1TDP1L3MBTL1OPRM1
SCHEMBL513972 0.73 HSD11B1 (0.36) OPRM1OPRL1
SCHEMBL513971 0.73 HSD11B1 (0.36) OPRM1OPRL1
SCHEMBL514026 0.70 XIAP (0.37) KDM4EALDH1A1MAPTCYP1A2CYP3A4
SCHEMBL14915911 0.69
SCHEMBL17510774 0.68 OPRM1 (0.53) OPRM1OPRL1
SCHEMBL2030574 0.68 CES2 (0.42) CES2CES1OPRM1OPRL1RAB9A
SCHEMBL513117 0.68 ALDH1A1 (0.47) KDM4EALDH1A1MAPTCYP1A2CYP3A4
SCHEMBL627867 0.68 CES2 (0.64) CES2CES1TDP1L3MBTL1ALDH1A1
SCHEMBL1559660 0.66 OPRM1 (0.33) OPRM1OPRL1KDM4EMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130102605-A1 INHIBITORS OF AKT ACTIVITY LIANG PENG (CN) 2013-04-25 US disclosed
US-20120028918-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING SAME GLAXO WELLCOME MANUFACTURING PTE LTD. (SG) 2012-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028918-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING SAME PIK3CA, G6PC1, PIK3C2B CES2 979/4885CES1 1170/4885TDP1 2363/4885
US-20130102605-A1 INHIBITORS OF AKT ACTIVITY PIK3CA, PIK3CD, AKT2 CES2 3519/4885CES1 2170/4885TDP1 2175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.